In thyroid cancer, our study indicates that the methylation of TERT promoter is as prevalent as TERT promoter mutations among clinically aggressive tumours (50% vs. 45.7% respectively), although with less specificity for disease prognosis. This evidence concerns the gene TERT and neoplasm.